MetS is considered as a chronic low-grade inflammatory state evidenced by elevated levels of several inflammatory biomarkers [e.g., C-reactive protein (CRP)] and cytokines [e.g., interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α)] [8,9]. The gene discussed is IL1B; the disease is metabolic syndrome.